The round, yellow pill debossed with “TL 706” in black ink is Methylphenidate Hydrochloride Extended-Release (18 mg), manufactured by Trigen Laboratories (also distributed under brand equivalents such as Relexxii). It is a central nervous system (CNS) stimulant primarily prescribed to manage Attention Deficit Hyperactivity Disorder (ADHD) and is classified as a Schedule II (C-II) controlled substance in the United States due to a high risk of abuse, dependence, and diversion.
Pill Identification
Attribute – Specification
- Imprint – TL 706 (printed in black ink)
- Active Ingredient – Methylphenidate Hydrochloride (18 mg)
- Color – Yellow
- Shape – Round
- Release Type – Extended-Release (ER / Osmotic-like Delivery)
- Distributor / Labeler – Trigen Laboratories, LLC / Osmotica Pharmaceutical
- Drug Class – Central Nervous System (CNS) Stimulant / Phenethylamine
- DEA Schedule – Schedule II (C-II)
Mechanism of Action
Methylphenidate acts as a norepinephrine-dopamine reuptake inhibitor (NDRI):
- Transporter Blockade: It selectively binds to and blocks the dopamine active transporter (DAT) and the norepinephrine transporter (NET) in the presynaptic neuronal membrane.
- Synaptic Neurotransmission: By preventing the reuptake of these monoamine neurotransmitters, it increases extracellular concentrations of dopamine and norepinephrine in the synaptic cleft, particularly within the prefrontal cortex and striatum.
- Extended-Release Profile: The tablet is formulated with an immediate-release overcoat (which dissolves rapidly to provide initial daytime focus) combined with an extended-release core that releases methylphenidate continuously over 10 to 12 hours to avoid midday dosing.
Indications and Dosage
- Primary Indication: Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children (6 years and older), adolescents, and adults.
- Dosing in Stimulant-Naïve Patients:
- Children/Adolescents: Typically started at 18 mg once daily in the morning.
- Adults: Usually started at 18 mg or 36 mg once daily in the morning.
- Dose Titration: May be adjusted in 18 mg increments at weekly intervals based on clinical response, up to a maximum daily dose of 54 mg/day in children (ages 6–12) or 72 mg/day in adolescents and adults.
- Administration:
- Take once daily in the morning with a full glass of water, with or without food.
- Do not chew, crush, or divide: The pill must be swallowed whole to preserve the extended-release mechanism; crushing or dissolving can cause rapid, life-threatening drug dumping.
Side Effects
Common Side Effects
- Decreased appetite and weight loss
- Insomnia and sleep disturbances (especially if taken late in the day)
- Dry mouth, nausea, and dyspepsia
- Headache, dizziness, and mild tremors
- Increased heart rate (tachycardia) and elevated blood pressure
- Nervousness, irritability, or anxiety
Serious Adverse Reactions
- Cardiovascular Events: Significant hypertension, arrhythmias, myocardial infarction, or stroke.
- Psychiatric Complications: New or worsening psychosis, mania, extreme aggression, or auditory/visual hallucinations (even in patients without prior psychiatric history).
- Peripheral Vasculopathy (Raynaud’s Phenomenon): Episodic digital blanching, numbness, tingling, or pain in fingers/toes.
- Priapism: Prolonged, painful erections requiring immediate surgical/medical intervention to prevent permanent tissue damage.
- Suppression of Growth: Long-term use in children can result in temporary slowing of growth rate (height and weight).
Precautions and Drug Interactions
- Monoamine Oxidase Inhibitors (MAOIs): Concurrent use or use within 14 days of discontinuing an MAOI (e.g., phenelzine, selegiline) is strictly contraindicated due to the risk of fatal hypertensive crisis.
- Cardiovascular Pre-screening: Stimulants should generally be avoided in patients with known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, or severe coronary artery disease.
- Glaucoma & Pre-existing Tics: Contraindicated or used with extreme caution in patients with marked anxiety/agitation, motor tics, Tourette’s syndrome, or narrow-angle glaucoma.
- Alcohol Interaction: Alcohol can alter the release rate of certain extended-release formulations, increasing rapid absorption and CNS toxicity.
Critical Warnings (FDA Boxed Warnings)
- Abuse, Misuse, and Addiction: Methylphenidate carries a high potential for abuse and misuse, which can lead to substance use disorder, overdose, and death. Patients should be assessed for risk of addiction prior to prescribing and monitored continuously.
- Cardiovascular Risk / Sudden Death: Sudden unexplained death has been documented in children and adults with structural heart defects taking CNS stimulants at standard doses. Blood pressure and heart rate must be monitored regularly during therapy.